Lupin Ltd — Capital/Financing Update 2019

Nov 22, 2019

Press Release

==> picture [45 x 55] intentionally omitted <==

BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPCIN

Lupin launches Hydrocortisone Valerate Cream

Mumbai, Baltimore, November 22, 2019: Pharma major Lupin Limited (Lupin) announced the launch of Hydrocortisone Valerate Cream USP, 0.2%, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier.

Lupin’s Hydrocortisone Valerate Cream USP, 0.2%, is the generic equivalent of Westcort® Cream, 0.2%, of Sun Pharmaceutical Industries Inc. It is indicated for the relief of the Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in adult patients.

Hydrocortisone Valerate Cream USP, 0.2%, (RLD: Westcort® Cream) had an annual sales of approximately USD 11.5 million in the U.S. (IQVIA MAT September 2019).

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded and generic formulations, biosimilar products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 8[th] largest generics pharmaceutical company by revenues (June 30, 2019, Bloomberg LTM). The Company is the 3[rd] largest pharmaceutical player in the US by prescriptions (IQVIA MAT September 2019); 3[rd] largest Indian pharmaceutical company by global revenues (June 30, 2019, Bloomberg LTM); 6[th] largest company in the Indian Pharmaceutical Market and 5[th] largest generic pharmaceutical player in Japan (IQVIA MAT September 2019).

For the financial year ended March 31, 2019, Lupin’s Consolidated sales and Net profits before exceptional items were at INR 163,694 million (USD 2.34 billion) and INR 9,466 million (USD 136 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter at – www.twitter.com/lupinglobal

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3[rd] Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

For further information or queries please contactArvind Bothra Head – Investor Relations and M&A / Corporate Communications Email: arvindbothra@lupin.com Ph: +91-22-66408237

*Safe Harbor Statement

Westcort® is a registered trademark of Sun Pharmaceutical Industries Inc.